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Abstract 
The extent to which ART (anti-retroviral therapy) reduces HIV transmission has received attention in 
recent years. Using data on the relationship between transmission and viral load we show that 
transmission saturates at high viral loads. We fit a power-law model and an exponential converging to 
an asymptote. Using data on the viral load in HIV-positive people we show that ART is likely to 
reduce transmission by 91.6% (81.7%−96.2%) under the first and 99.5% (98.5%−99.8%) under the 
second model. 
 The role of the acute phase in HIV transmission is still debated. High levels of transmission 
during the acute phase have been used to argue that failure to identify people in the acute phase of 
HIV may compromise the impact of treatment on preventing new infections and that having 
concurrent sexual partners during the acute phase is an important driver of the epidemic. We show that 
the acute phase probably accounts for less than 1% of overall transmission. We also show that even if 
a significant proportion of infections are transmitted during the acute phase, this will not compromise 
the impact of treatment on population levels of transmission given the constraint implied by the 
doubling time of the epidemic.  
 This analysis leads to other relevant conclusions. First, it is likely that discordant-couple studies 
significantly underestimate the risk of infection. Second, attention should be paid to the variability in 
set point viral load which determines both the infectiousness of HIV-positive people and the 
variability in the susceptibility of HIV-negative people. Third, if ART drugs are in short supply those 
with the highest viral load should be given priority, others things including age, gender and 
opportunistic infections being equal, but to reduce transmission ART should be offered to all those 
with a viral load above about 10k/mm.3 
 
Introduction 
Understanding the relationship between HIV viral 
load and transmission is essential if we are to 
understand the dynamics of HIV and, in particular, 
the impact of ART on HIV transmission. It is 
generally accepted that the risk of HIV-
transmission increases as the plasma viral load 
increases but precise data that can be used to 
address this question are few, especially at high and 
low viral loads. Transmission at low viral loads 
determines the impact that anti-retroviral therapy 
has on transmission; transmission at high viral 
loads determines the importance of transmission 
during the acute phase of HIV infection; 
transmission at intermediate viral loads determines 
the rate at which HIV spreads through a population. 
 Previous attempts to establish a relationship 
between transmission and viral load assume a 
power-law relationship. Here we present an 
alternative model in which transmission increases 
linearly with viral load when the viral load is low 
but converges to an asymptote when the viral load 
is high. We consider the implications of both 
models for the impact of ART on the reduction in 
viral load and of ART on HIV transmission. 
 We use data on the viral load over time to 
establish the duration and magnitude of the viral 
load during the acute stage of infection as 
compared to the chronic stage and to estimate the 
proportion of transmission events that take place 
during the acute phase. Some have argued that the 
acute stage of HIV infection lasts for up to five 
months during which time the risk of infecting 
another person is up to 30 times greater than in the 
subsequent chronic stage of infection with 
important implications for the dynamics and control 
of HIV. We show that this is very unlikely to be the 
case and attempt to reconcile our conclusions with 
this point of view. 
 Finally, we consider likely biases in current 
estimates of the risk of infection per sexual 
encounter, based on studies of discordant couples, 
and the use of viral load as a way of triaging 
patients for ART. 
Data 
For the frequency distribution of viral load among 
people in a generalized HIV epidemic we use data 
from a cross-sectional survey of young men in 
Orange Farm, South Africa.1  
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 Attempts to measure the relationship between 
viral load and transmission have either presented 
the risk per sexual contact2,3 or the risk per unit 
time and have included studies of discordant 
couples3-10 and vertical transmission from mothers 
to their children.11 To determine the relationship 
between transmission and plasma viral load we use 
data from three studies. The first by Attia et al.6 is a 
meta-analysis of 6 earlier studies, the second by 
Donnell et al.12 is from a study of the impact of 
treating HSV-2 on HIV-1 transmission, the third by 
Lingappa et al.13 is based on prospective data from 
HIV-1 sero-discordant couples in East and southern 
Africa. To determine the relationship between 
transmission and viral load in genital secretions we 
use data from a prospective study of heterosexual 
sero-discordant couples in Africa that considered 
male to female and female to male transmission 
separately.14 These studies all measured the number 
of transmission events per year which depends on 
the frequency of sexual encounters. 
Methods 
Estimating the distribution of viral load 
In all of the studies of the relationship between 
transmission and viral load the authors only publish 
the number of transmission events in fixed ranges 
of viral load and we need to estimate the mean viral 
load for each range. To do this we start from the 
data in Figure 1 and determine the Box-Cox 
transformation15  
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Figure 1. Measure and observed probability density 
function (p.d.f.) of viral load in young men from a cross-
sectional survey carried out in Orange Farm, South 
Africa.1 
 The Box-Cox parameter is λ = 2.58 resulting in 
a normal distribution with a mean value of 20.8 and 
a standard deviation of 9.4. We then assume that in 
the study by Attia et al.6 the density function is the 
same as in Orange Farm1 while in the study by 
Donnell et al.12 we keep the same value of the Box-
Cox parameter but fit a cumulative normal 
distribution to the observed numbers of people in 
each range of the viral load16 (see Appendix 1). For 
the Orange Farm study the mode of the viral load 
distribution is 95k virions/mL while in the Donnell 
et al.12 study it is 29k virions/mL. 
Models of transmission as a function of viral 
load 
We use two models to fit the data on transmission 
as a function of viral load. The first, used in all four 
of the publications cited,6,12,13 assumes a power-law 
relationship between transmission and viral load; 
the second, which we develop here, assumes that at 
very low viral loads transmission increases linearly 
with viral load but converges exponentially to an 
asymptote when the viral load is very high. The 
equation for the power-law model is 
 T V σβ=   2 
and for the converging-exponential model is 
 ( )1 e VT ρα= − . 3 
so that at low values of the viral load 
 T Vαρ≈  4 
Results 
Distribution of viral load 
The distribution of viral load before people start 
ART is variable but seldom published. For the data 
in Figure 1, measured in a cross-sectional survey of 
young men in Orange Farm, South Africa,1 the 
mode of the distribution is at 53k/mL but with 95% 
of the distribution lying between 224/mL and 
882k/mL, spanning more than three orders of 
magnitude. Those with a viral load in the region of 
106/mL will be more infectious than those with a 
viral load of 100/μL. But not only will treating 
those with the highest viral load have the greatest 
individual benefit, since survival decreases as viral 
load increases, but it will also have the greatest 
public health benefit by reducing transmission. 
 
Transmission as a function of plasma viral load 
Figure 2 shows the data for the three studies of 
transmission as a function of plasma viral load 
fitted to the two models.  For the data from Attia et 
al.6 (Figure 2 A and B) the exponential model gives 
a statistically good fit (p = 0.8) while the power-law 
model does not (p = 0.0008). For the data from 
Donnell et al.12 (Figure 2 C and D) and Lingappa et 
al.13 (Figure 2 E and F) both models give 
statistically acceptable fits. On the basis of these 
data alone we cannot say with confidence that 
either model is better. 
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Figure 2. Two models fitted to data on the annual risk of infection in a discordant couple as a function of plasma viral load. 
Left: Converging-exponential (Equation 3). Right: Power-law (Equation 2). Data A and B: Attia et al.6; C and D: Donnell et 
al.12; E and F Lingappa et al.13 The fitted parameters and the significance levels for the fits are A: α = 0.083 (0.062−0.107) 
infections per year, ρ = 2.23 (2.14−2.31) mL/virion, p = 0.80; B: β = 0.32 (0.30−0.33), σ  = 0.0019 (00.15−0.023), 0.0006;  
C: α = 0.032 (0.024−0.042) infections per year, ρ = 2.31 (2.25−2.37) mL/virion, p = 0.38; D: β = 0.45 (0.42−0.47), σ  = 
0.00017 (0.00013−0.00022), 0.30; E: α = 0.053 (0.042−0.066) infections per year, ρ = 2.35 (2.30−2.39) mL/virion, p = 0.11; 
F: β = 0.43 (0.41−0.45), σ  = 0.00027 (0.00021−0.00034), p = 0.39. 
 Under the converging-exponential model, 
reducing the viral load from 50k/mL to 100/ml 
gives a relative risk for HIV-transmission of 0.53% 
(0.18% to 1.52%) corresponding to a 189 (66 to 
556) fold reduction in transmission. Using the 
power-law model the corresponding relative risk is 
8.4% (3.8% to 18.3%) corresponding to a 12 (5 to 
26) fold reduction in transmission. Both reductions 
are substantial but their difference is significant and 
it will be important to establish which one is more 
likely to be correct since the extrapolation to low 
values of viral load depends critically on the choice 
of model. Both estimates are consistent with the 
results of a recent randomized controlled trial 
which showed that ART reduces transmission by 
96% (73%−99%).17  
 Under the converging-exponential model, 
transmission saturates when the log-viral load is 
greater than 4.42 (4.40−4.44) and the viral load is 
26.0 (24.8−27.3) k/mL. Under the power-law 
model, transmission increases as the viral load to 
the power of 0.32 (0.30−0.34), so that the increase 
is less than linear. In either case a biological 
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explanation for the observation that transmission 
saturates at high values of viral load is needed. 
 The key features of the fits in Figure 2 are 
summarized in Table 1. To obtain an estimate of the 
reduction in transmission as viral load falls we 
compare the risk of infection at a viral load of 
100/μL, which is achievable with anti-retroviral 
therapy,18 with the risk at a viral load of 50k/mL, 
close to the mode of the distribution. 
Table 1. Model 1 assumes that transmission increases linearly with viral load at low viral loads but converges 
exponentially to an asymptote. Model II assumes a power law relationship between transmission and viral load. 
RR is the risk of transmission at a viral load of 100/μL compared to that at 105/mL. SVL is the saturation viral load 
(see text for details). Power is the power in the power-law relation between transmission and viral load. The data 
are plotted in Figure 2. The estimates in each of the first three rows are not significantly different (p > 0.67 in all 
cases) but the estimates in the bottom row are significantly over-dispersed (p < 0.0001). Mean values are therefore 
weighted means using the estimated errors for the first three rows and unweighted means, with the error calculated 
from the residuals, in the bottom row. 
Model Attia et al.6 Donnell et al.12 Lingappa et al.13 Mean 
RR (%) 0.91 (0.38−2.43) 0.46 (0.20−1.37) 0.37 (0.18−1.01) 0.53 (0.18−1.52) 
I 
Log10(SVL) 4.04 (3.69−4.36) 4.39 (4.12−4.65) 4.56 (4.33−4.76) 4.42 (4.40−4.44) 
RR (%) 14.05 (7.76−31.4) 6.19 (3.08−13.0) 6.87 (3.60−12.80) 8.35 (3.80−18.3) 
II 
Power 0.32 (0.30−0.33) 0.45 (0.42−0.47) 0.43 (0.41−0.45) 0.32 (0.30−0.34) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Two models fitted to the annual risk of infection in discordant couples as a function of viral load in 
genital secretions.14 Left: converging-exponential (Equation 3). Right: power-law (Equation 2). A and B: female 
to male transmission; C and D: male to female transmission. A: α = 0.025 (0.017−0.035) infections per year, ρ = 
1.55 (1.28−1.78) mL/virion, p = 0.16; B: β = 0.23 (0.21−0.24), σ  = 0.0030 (00.26−0.035), 0.96;  C: α = 0.047 
(0.030−0.071) infections per year, ρ = 1.62 (1.36−1.82) mL/virion, p = 0.55; D: β = 0.21 (0.15−0.25), σ  = 0.0067 
(0.0042−0.0101), p = 0.22.  
Transmission as a function of genital viral load 
In determining HIV transmission, the viral load in 
genital secretions is likely to be more important 
than the viral load in plasma. Figure 3 shows the 
limited available data and the fitted curves for the 
relationship between transmission and viral load in 
genital secretions. Both models give acceptable fits 
to the data so that one cannot determine which 
model is better on the basis of the statistical fit 
 The data in Figure 3 are summarized in Table 2. 
The asymptotes are slightly, but not significantly, 
lower than the asymptotes in Figure 2 but the data 
in Figure 3 suggest that the saturation viral load in 
genital secretions is 197 (90−430) times, or about 
  5/14  
two orders of magnitude, less than in the plasma. 
Using the power-law model gives a correspond-
ingly low value for the power in the fit. The reason 
for the saturation effect remains to be explained. 
These data are less precise than the data based on 
plasma viral load and reducing the genital viral load 
to 100/μL would reduce transmission by 92.6% 
(31.9%−99.2%) using Model I and by 84.7% 
(21%−97.0%) using Model II. 
Table 2. Relative risk of transmission at high and low viral loads, the saturation viral load and the power-law 
relationship between viral load and transmission. Model 1 assumes that transmission increases linearly with viral 
load at low viral loads but converges exponentially to an asymptote. Model II assumes a power law relationship 
between transmission and viral load. RR gives the risk of transmission at a viral load of 10/μL compared to that at 
105/mL. SVL is the saturation viral load (see text for details). Power is the power in the power law relation between 
transmission and viral load. The estimates do not differ significantly; p > 0.95 in all cases. M: male; F: female. 
Model  Baeten et al. F to M14 Baeten et al. M to F14 Mean 
RR (%) 8.72 (1.82−37.1) 6.17 (1.24−32.4) 7.44 (0.81−68.1) 
I 
Log10(SVL) 2.04 (1.57−2.57) 2.20 (1.68−2.69) 2.12 (1.51−2.98) 
RR (%) 14.31 (5.11−40.8) 17.0 (5.07−74.9) 15.25 (2.95−79.0) 
II 
Power 0.23 (0.21−0.24) 0.21 (0.15−0.25) 0.23 (0.20−0.26) 
 
 
 
 
 
 
 
 
Figure 4. Viral load as a function of time19 after 
infection fitted to an exponential converging to an 
asymptote that determines the peak viraemia followed 
by a logistic decline to the set point. The two curves 
represent the longest (25 days) and shortest (12 days) 
durations of the acute phase that are consistent with the 
data.  
Viral load during the acute phase 
After a person has been infected with HIV the viral 
load increases rapidly with a doubling time of 20.5 
(18.2–23.4) hours.19 Assuming that each infection 
is established from a single virion, it will take about 
3.5 weeks to reach a concentration of 105 virions 
per mL. in a person with 5 litres of blood. In order 
to fully characterize the acute phase, HIV negative 
people would have to be tested once or twice a 
week to ensure that the initial rise is accurately 
captured. An early study, based on data from newly 
infected plasma donors19 is shown in Figure 4. 
Using the full-width at half-maximum above the set 
point (FWHM), on a log-scale, gives an acute phase  
duration of between 12 and 25 days, a peak 
viraemia of 105.4 = 251k per mm3 and a set point 
viraemia of 104.1 = 13k per mm3. 
 Preliminary, and only partial, results from an 
ongoing study have been reported by Robb.20 
People from high risk populations in Uganda, 
Kenya, Tanzania and Thailand are tested for HIV 
twice a week and as soon as they are found to be 
HIV positive they are followed up intensively for 
the first month and then for up to five years. A 
subset of the data, taken from a presentation,20 are 
shown in Figure 5. Averaged over all of the data 
sets the FWHM is 17 ± 3 days, the peak viraemia is 
106.6±0.4 = 3.0 (1.6−10.0) million virions per mm3 
and the set point viraemia is 104.5±0.5 = 32 
(10−100) thousand virions per mm3. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Data from the acute phase study of Robb.20 The 
data have been extracted from a presentation. The fitted 
curves are exponentials converging to an asymptote 
followed by a logistic decline to a steady state 
 In another study Powers et al.21 cite data from 
Pilcher et al.22 for which the FWHM is 2.3 weeks 
and which Powers et al.21 interpret as giving an 
acute phase duration of two weeks (Powers et al.,21 
their supporting information, Figure 1). 
 Taken together these data suggest that the acute 
phase lasts for about 2 to 3  weeks, that the log10 of 
the peak viraemia per mm3 is 6.0 ± 1.0 while the 
log10 of the set point viraemia per mm3 is 30 times 
lower at 4.5 ± 0.5. 
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Transmission during the acute phase 
It has been suggested that transmission in the acute 
phase contributes a significant proportion of overall 
transmission.21,23 Given the difficulty of finding 
people during the short acute phase this has 
important consequences for the impact of treatment 
on transmission.  
 We first consider the risk of infection during the 
acute as compared to the chronic phase of infection. 
Using the converging-exponential model (Figure 2 
A, C and E) and assuming that the log10 of the set 
point viral load is 6.0 in the acute phase and 4.5 in 
the chronic phase, the risk of infection in the acute 
phase is between 1% and 2% higher than in the 
chronic phase, and less than 7% higher, with 95% 
certainty, for all three sets of data. Using the power-
law model, with a power of 0.23 (Table 2) suggests 
that transmission in the acute phase is 2.2 (2.0−2.5) 
times higher than in the chronic phase. Given that 
the chronic phase lasts for an average of about 11 
years, these data suggest that the proportion of 
transmission that takes place during the acute phase 
is between about 0.4% using the converging-
exponential model, and 0.8% using the power-law 
model. In either case it is unlikely that the high 
viral load during the acute phase makes a 
significant difference to the rate of infection. 
Transmission among discordant couples 
We attempt to reconcile the observation that the 
relatively high viral load in the acute phase does not 
contribute significantly to overall transmission with 
claims that transmission among discordant couples 
is 7.2 (3−17) times higher in the first five months 
after infection than in the chronic stage.24 In other 
analyses of the same data transmission was 26 
(13−54) times higher in the first 2.9 months25 or 13 
times higher in the first 2.5 months26 after infection 
than in the chronic stage. These two estimates are 
not themselves inconsistent, given the uncertainty 
in the original data and the assumptions concerning 
the duration of the acute phase. However, if the 
acute phase lasts for only two weeks, the infectivity 
during this short time would have to be of the order 
of 70 (30−170) times higher than during the chronic 
phase. 
 Three factors may help to reconcile these 
observations. The first is that, as Wawer et al.24 
note in their original paper, genital ulcer disease is 
significantly associated with the risk of HIV 
infection and the risk of HIV infection may 
increase by 6.0 (2.6−14.0) times in those recently 
infected with Herpes simplex (HSV) 1 as compared 
to those with an established HSV-1 infection or 
without HSV-1 infection.27 Given the high 
incidence of HSV-1 in parts of Africa28 it is not 
unlikely that people who are infected from outside 
the relationship will be infected at about the same 
time with both HIV-2 and HSV-1 with a 
corresponding increase in the likelihood that they 
will infect their sexual partners. 
 The second factor is that different people are 
more or less susceptible to HIV-infection.29 
Furthermore, there is evidence that young women 
are at especially high risk of HIV infection for both 
biological and social reasons and Wawer et al.24 
show that the risk of infection is 2.2 (1.2−4.0) times 
higher in those younger then 30 years of age as 
compared to those older than 30 years of age. In a 
cohort study those that are most susceptible to 
infection will be infected first leaving those that are 
at lower risk of infection to be infected later. 
 The third factor is that different people are more 
or less infectious to others. As shown in Figure 1 
and Figure 5, the set-point viral load varies among 
people infected with HIV. Since those with high 
set-point viral loads will be more likely to infect 
their partners first the transmission probability is 
expected to fall over time spent in the cohort. To 
estimate the importance of this, we use the risk of 
transmission as a function of viral load given in 
Figure 2A and let survival in years, S, vary as the 
plasma viral load/mm3 as in Appendix 4. 
 We let the viral load distribution in incident 
HIV cases be log-normally distributed with a mean 
value of the log10(viral load/mm3) of 5.14 and a 
standard deviation of 0.78 (Appendix 4). We can 
then estimate the probability that the index case 
will remain alive and the susceptible partner will 
remain uninfected, as a function of time, and hence 
the average transmission rate as a function of time 
since the index case was infected given that the 
index case is alive and the partner is still 
uninfected.  We also need to estimate the initial rate 
of transmission immediately after the index case is 
infected. To do this we note that the initial 
epidemic doubling time in heterosexual epidemics 
is typically about 15 months30 so that the 
transmission rate, at the start of the epidemic, is 
about 0.8 per year. This initial transmission rate 
implies that after five months 28% of people in 
discordant relationships should be infected which is 
not significantly different from the estimate given 
by Wawer et al.24 who found that 10/23 or 43% 
(23%−66%) of negative partners in discordant 
couples were infected in the first five months 
although this latter estimate does seem to be very 
high. 
 Proceeding in this way we are able to obtain the 
risk of transmission in discordant couples, as a 
function of time spent in the cohort, allowing for 
the fact that HIV-positive people with high viral 
load will both be more likely to infect their partners 
sooner and will be more likely to die sooner. 
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Figure 6. The risk of transmission in a discordant 
couple compared to the risk immediately after the 
index partner becomes infected as a function of time 
spent in the cohort allowing for the fact that those 
with high viral load are most infectious but will also 
die soonest. 
 Figure 6 suggests that after ten years 
transmission rates in discordant couples may have 
fallen by about 60% which is still significantly less 
than the decline in relative risk estimated by Wawer 
et al.24 assuming that their ‘prevalent cases’ had 
been infected for an average of ten years. 
 Variability in the infectiousness and survival of 
people resulting from the variability in viral load 
may explain some, but not all, of the variability 
given in the study by Wawer et al.24 It would be of 
interest to include variability in the susceptibility to 
infection, where such data are available, to see if 
high rates of transmission soon after infection with 
HIV can be used to explain the results of Wawer et 
al.,24 without appeal to the acute phase, and also 
resolve the apparent paradox that assumed rates of 
transmission appear to be insufficient to sustain an 
epidemic of HIV. 
High rates of transmission in the acute phase∗ 
This analysis suggests that the duration of the acute 
phase is too short and the increased risk of infection 
during the acute phase too small to have a 
significant impact on the overall dynamics of the 
epidemic. However, there are those that maintain 
that the duration of the acute phase may be several 
months and that during this time the risk of 
infection per sex act maybe increased by up to 
about 30 times.21,23 Given that this could be the case 
it behoves us to consider the consequences that this 
would have for treatment as prevention.  
 The key point is this: one of the few directly 
observed parameters concerning the epidemiology 
of HIV is the initial doubling time which, in South 
Africa, is 1.25 ± 0.25.30 Since the acute phase lasts 
for considerably less time than the chronic phase, 
the greater the relative risk of transmission in the 
acute phase the smaller must be the value of R0 to 
                                                          
∗ For an earlier, but less complete, discussion of the issues 
raised in this section see: http://arxiv.org/abs/1105.2767. 
maintain the same initial doubling time. Indeed, if 
we know the initial doubling time (the growth rate r 
in Appendix 2, Equation  11), the relative risk of 
infection in the acute phase and each of the four 
chronic phases (λi/λ0 in and 9), and the duration of 
each of the four stages (1/δi in Appendix 2, 
Equations 8 and 9) in Appendix 3, we can 
determine the value of λ0 that gives the observed 
rate of increase of the prevalence at the start of the 
epidemic and hence the value of R0 (Appendix 2, 
Equations 16). 
 Values of R0, as a function of the relative risk of 
transmission during the acute phase and the 
duration of the acute phase in months, are given in 
Figure 7A. Without ART the value of R0 is 5.8 
(brown rectangle). With RR = 2.1 and DAP = 2 mo. 
(green ellipse) R0 falls to 5.4. With RR = 8.3 and 
DAP = 6 mo. (red ellipse) R0 falls to 3.0. With RR = 
26 and DAP  = 6 mo. (blue ellipse) R0 falls to 2.3. 
As expected the higher the rate of transmission 
during the acute phase the lower the value of R0. 
 The boundaries of the ellipses indicate the 
uncertainty in the point estimates which are 
considerable. Assuming, as noted above, that in the 
Hollingsworth et al.25 study the high values of DAP 
correspond to low values RR, and vice versa, we 
slant the corresponding confidence ellipse at an 
appropriate angle. This also serves to show that if 
we let DAP = 6 mo. the estimates made by 
Hollingsworth et al.25 and the Wawer et al.24 are 
not significantly different. 
 It is important to note that testing people 
regularly at intervals of one year, say, is more 
efficient than testing people randomly but once a 
year on average. In the latter case some people are 
never tested and some people are tested more often 
than is strictly necessary. This is discussed further 
in Appendix 3. Figure 7B shows what happens if 
people are tested randomly but once a year on 
average. With RR = 1, the value of R0 falls to 0.58 
(brown rectangle). With RR = 2.1 and DAP = 2 mo. 
R0 falls to 0.61. With RR = 8.3 and DAP = 6 mo. R0 
falls to 0.84 and with RR = 26 and DAP  = 3 mo. R0 
falls to 0.90. In all three cases R0 still falls below 1 
although with the two higher estimates of RR it is 
only 10% to 20% below 1 which allows for little 
margin for error.  
 Figure 7C shows what happens if the average 
testing interval is reduced to six months. With RR = 
1, R0 falls to 0.29 (brown rectangle). With RR = 2.1 
and DAP = 2 mo. R0 falls to 0.34. With RR = 8.3 
and DAP = 6 mo. R0 falls to 0.61 and with RR = 26 
and DAP  = 3 mo. R0 falls to 0.75. Even in the worst 
case (RR = 26, DAP = 3 mo.) R0 is significantly 
less than 1. 
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Figure 7. The value of R0 for an epidemic with a doubling time of 15 months as a function of the 
duration of the acute phase and the relative transmission rate in the acute phase compared to the chronic 
phase. Colours correspond to different values of R0 and the numbers in circles give the values on 
different contour lines. A without ART; B and C with random testing once a year or twice a year, on 
average; D and E with regular testing once a year or twice a year. Brown rectangle: RR = 1; green 
ellipse: RR = 2.1, DAP = 1 mo.; ellipse RR = 8.3, DAP = 6 mo.; blue ellipse: RR = 26, DAP = 3 mo. 
The ellipses are 95% confidence limits of the point estimates. 
 
 Figure 7D shows what happens if people are 
tested regularly once a year. With RR = 1, the value 
of R0 again falls to 0.29 (brown rectangle). With 
RR = 2.1 and DAP = 2 mo. R0 falls to 0.38. With RR = 8.3 and DAP = 6 mo. R0 falls to 0.70 and with RR = 26 and DAP  = 3 mo. R0 falls to 0.82. Again, even 
in the worst case (RR = 26, DAP = 3 mo.) R0 is 
significantly less than 1. 
 Figure 7E shows what happens if people are 
tested regularly twice a year. With RR = 1, R0 falls 
to 0.14 (brown rectangle). With RR = 2.1 and DAP = 2 mo. R0 falls to 0.21. With RR = 8.3 and DAP = 6 
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mo. R0 falls to 0.45 and with RR = 26 and DAP  = 3 
mo. R0 falls to 0.68. Even in the worst case (RR = 
26, DAP  = 3 mo.) R0 is again significantly less than 
1. 
 We have three estimates of RR, the relative risk 
of infection, and DAP, the duration of the acute 
phase ranging from 2.1 over 2 months to 26.2 over 
3 months giving values of R0 ranging from 5.8 to 
2.3. The high estimates for RR may be over-
estimates. They are both based on the data from 
Rakai24 and discordant couple studies in which one 
partner is already infected will select against those 
couples who are most infectious and therefore no 
longer sero-discordant, as discussed above. 
Furthermore, the high values of RR with long 
values of DAP imply values of R0 ≈ 2 which seems 
unlikely; if this were the case HIV should be 
relatively easy to eliminate through minor changes 
in behaviour and the epidemic should be much less 
stable.  
 Even if we adopt the most pessimistic view and 
assume that the relative risk of infection is 26 times 
higher during an acute phase that lasts for 3 months 
annual testing and immediate treatment has the 
potential to reduce R0 to less than 1 and with any 
further contribution to prevention will guarantee 
elimination in the long term. Testing people 
regularly, on an annual basis, is more effective than 
random testing because under random testing some 
people will be tested very frequently, which is not 
necessary, while others will be tested very 
infrequently which is not ideal. With regular testing 
even the most pessimistic view reduces R0 to 0.82 
and will probably lead to elimination. As expected, 
testing people twice a year reduces R0 even further 
and under all assumptions about the acute phase 
would guarantee elimination. 
Using viral load to triage patients 
Using CD4+ cell counts to decide which patients 
are in greatest need of ART is flawed for a number 
of reasons. First, CD4+ cell counts in HIV-negative 
people vary widely. In Orange Farm, South Africa, 
95% of HIV-negative people have CD4+ cell 
counts in the range 380/μL to 1550/μL.1 About 
10% of the population have CD4+ cell counts 
below 500/μL before they are infected with HIV 
and given that CD4+ cell counts drop by about 25% 
immediately after sero-conversion 33% of people 
will have CD4+ cell counts below 500/μL within 
two weeks of being infected with HIV. 
 Second, CD4+ cell counts vary widely among 
populations. In Orange Farm, South Africa, the 
median CD4+ cell count in HIV-negative people is 
1115/μL1 while in Botswana it is   599/μL.31 
 Thirdly, if we consider a country such as 
Zimbabwe, where the prevalence of infection first 
rose and then fell rapidly, we can show that in 1985 
about 10% of those infected had a CD4+ cell count 
below 350/μL but by 2005 about 52% had a CD4+ 
cell count below 350/μL.  
 Finally, at very low CD4+ cell counts people 
are likely to have easily diagnosed AIDS defining 
illnesses and at high CD4+ cell counts mortality 
rates are relatively insensitive to CD4+ cell 
counts.32 
 Since viral load is a much better prognostic 
indicator than CD4+ cell counts of both survival 
and infectiousness, some scientists have suggested 
using viral load tests to triage patients for ART and 
trials are being developed in which people will be 
started on ART if their viral load is less than 
50k/mL.33 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. R0(L), the value of R0 as a function of set point 
viral load. Blue numbers on the horizontal axis give the life 
expectancy for each viral load. For this model 〈R0(L)〉 = 6.0. 
 From the distribution of viral load at the sent 
point (Appendix 4), transmission as a function of 
viral load (Figure 2A), and the life expectancy as a 
function of viral load (Appendix 4, Figure 10) we 
can calculate the value of R0(L), the number of  
secondary infections for each primary infection as a 
function of viral load. This is shown in Figure 8. 
Those with a set-point viral load of 104.4 = 
25k/mm3 have the potential to contribute most to 
onward transmission but this will take place over 
about 20 years. Furthermore, only those with a set 
point viral load between 102.7 = 501/mm3 and 106.3 
= 2M/mm3 have a value of R0(L) > 1. 
 We can also plot the cumulative proportion of 
infections as a function of viral load as shown in 
Figure 9. We see that only 23% of infections are 
contributed by those with a viral load greater than 
100k/mm3 and 95% of all infections are contributed 
by those with a viral load between 102.9 = 794/mm3 
and 105.7 = 502k/mm3.  
 The caveat associated with this analysis is that 
at low viral loads the secondary infections will only 
occur over a long period of time. From the point of 
view of the individual patients one should give 
priority to those with the highest viral load, other 
things being equal. But to significantly reduce 
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transmission it will also be necessary to ensure that 
all those with a viral load above about 100k/mm3 
are offered ART since it is only below this level 
that infectiousness starts to decline rapidly with 
viral load (Table 1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. R0(L), the value of R0 as a function of set point 
viral load. Blue numbers on the horizontal axis give the life 
expectancy for each viral load. For this model 〈R0(L)〉 = 6.0. 
Conclusions 
There is strong evidence that transmission saturates, 
as viral load increases, at about 104 to 105 virions 
per mm3 and this demands a biological explanation. 
This implies that particularly high viral loads 
during the acute phase are unlikely to be important. 
 The available data suggest that people who are 
fully compliant with ART can reduce their 
infectiousness to others by at least 99.4% (98.5% to 
99.8%), consistent with the recent HPTN 052 study 
which gave a reduction of 96% (73%−99%).34 
 There is evidence that the duration of the acute 
phase is of the order of 2 to 3 weeks or about 0.3% 
of the average disease duration. This makes it even 
less likely that the acute phase contributes 
significantly to transmission; our best estimate is 
that the acute phase accounts for no more than 1% 
of total transmission. 
 In the unlikely event that the rate of 
transmission during the acute phase is about ten 
times higher than in the chronic phases and if the 
acute phase lasts, unrealistically, for two months, 
constraining the initial rate of increase of HIV- 
prevalence to between one and two years implies a 
value of R0 that is not much greater than 1. Even 
these extreme assumptions would not jeopardize 
the impact of treatment on transmission. 
 This analysis suggests that previous estimates of 
the risk of infection per unprotected sexual 
encounter, based on studies of discordant couples, 
considerably underestimate the risk of infection 
with important implications for interpreting models 
of HIV transmission. 
 What is needed in models of the impact of ART 
on the dynamics of HIV is a) consideration of the 
variability in the set point viral load and b) 
consideration of the variability in the susceptibility 
of individual people, and the implications that both 
of these have for the infectiousness and the survival 
of individual people. 
 Finally we note that, especially in relation to the 
acute phase, having concurrent partners is very 
unlikely to affect transmission in agreement with 
the conclusions of others.35 Of considerably greater 
interest than the currently sterile debate concerning 
concurrency36,37 would be a thoughtful and nuanced 
analysis of the implications of sexual network 
structures on the epidemic of HIV noting that 
concurrency, as currently and rather poorly defined, 
constitutes a small aspect of a bigger, and much 
more interesting, question. 
Appendix 1 Transforming and fitting 
the density function of viral load 
Let f(v) be the probability density function of v, the 
logarithm of the viral load to the base ten. We apply 
a Box-Cox transform to v so that the transformed 
variable w is 
 1vw
λ
λ
−=  5 
where v  is the geometric mean of the data. The 
density function of w is then 
 ( ) ( ) dvg w f v dw=  6 
where 
 1dvdw v
λ −=  7 
 We first transform the data using Equation 5 
and vary the parameter λ to get the best fit. We then 
fit a normal distribution to the transformed data and 
carry out the reverse transform and this give the 
curve shown in Figure 1. 
 For the data from Orange Farm, South Africa11 
the Box-Cox parameter is λ = 2.580 and the 
transformed data is normally distributed with a 
mean of 20.8 and a standard deviation of 9.4. 
 To determine the density function for the data in 
the study by Attia et al.6 we assume that the 
distribution is the same as for the Orange Farm 
data. To determine the density function for the data 
in the study by Donnell et al.12 and Lingappa et 
al.13 we apply the Box-Cox parameter for Orange 
Farm to these data and then fit the observed 
cumulative distribution function to a normal 
cumulative distribution function. In both cases, 
once we have the density function we can then 
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work out the mean value of the viral load within 
each range as given in the papers. 
Appendix 2 R0 and the growth rate for 
an n-stage model 
We want to introduce an acute phase but also keep 
four chronic stages in order to ensure that the 
survival distribution approximates the observed 
Weibull distribution with a shape parameter of 
2.25.38 We let λi be infectivity of people in stage  i 
of infection and δi be the rate at which people in 
stage i progress to the next stage of infection. Let Pi  
be the proportion of people in stage i (i = 0 for 
those that are uninfected) and assume that the death 
rate, when people leave from the last stage, match 
the recruitment rate so that we are dealing with 
proportions. The equations for the model are then 
(keeping the total population constant) 
 0 0
1
n
n n i i
i
P PP P λλ
=
= − ∑i  8 
 1 0 1 1
1
n
i i
i
P PP P δλ
=
= −∑i  9 
 1 1 , 2 toi j j j jP j nP P δδ − −= − =i  10 
At the start of the epidemic Pi ≈ 1 and, once the 
overall prevalence is increasing at a constant rate ρ 
the prevalence of those in each infected stage will 
be increasing at the same rate ρ so that 
 i iP rP=i     i = 1 to n 11  
and 
 
1
1 j
j
j
j
P
P
δ
ρ δ +
+
+=
    i = 1 to n 12  
From Equations 9 and 11 
 ( ) 1
1
n
i i
i
PP ρ δλ
=
+=∑  13 
Expanding Equation 12 gives 
 1 2 2
1 2 1 1
... 1n n
n
PP
P P
λλ λ
ρ δ ρ δ ρ δ+ + + =+ + +  14  
and substituting Equation 12 in Equation 13 we get 
 1
1 1
1
in
i
i
i j i
δλ ρ δ
−
= =
=+∑ ∏  15 
with δ0 = 1.  
 We now set duration of each stage, δi, the risk 
of infection in each stage, λi, relative to the first 
stage so that λ0 will be allowed to vary but the rest 
are then determined, and we set ρ to the observed 
rate of increase in prevalence at the start of the 
epidemic. We than vary λ0 to find the value that 
satisfies Equation15. We then calculate R0 directly 
as 
 0
1
n
i
ii
R λδ=
= ∑  16 
Appendix 3 Random versus regular 
testing 
Let the relative risk of infection vary with time 
since infection as RR(t) Then under random testing 
at a rate ρ year, the reduction in the overall 
transmission will be 
 0
0
e ( )
( )
t RR t dt
R
RR t dt
ρ∞ −
∞= ∫ ∫  17 
while under regular testing at an interval of τ years 
the reduction in overall transmission will be 
 
( )0
0
1 ( )
( )
t RR t
R
RR t
τ
τ
∞
−= ∫
∫  18 
Since we have estimates of the relative risk of 
transmission for different stages of infection, given 
that a person is alive, we approximate RR(t) with an 
appropriate step function. 
Appendix 4. Viral load and survival 
We assume that survival, after infection with HIV, 
is determined mainly by the set-point viral load and 
we wish to establish the relationship between viral 
load and survival. To do this we use the data on the 
distribution of viral load measure in Orange Farm, 
South Africa (Figure 1) and the survival 
distribution for people aged 15 to 24 from the 
Cascade Study39 where the observed survival 
distribution is Weibull with a median value of 12 
years and a shape parameter of 2.25.38 We first 
determine the cumulative probability that a person 
has a given viral load from the probability density 
function in Figure 1. We then determine the 
survival corresponding to this cumulative 
probability from the Weibull survival function 
noting that this can be done analytically. There is a 
further adjustment that needs to be made. The data 
in Figure 1 give the proportion of prevalent cases as 
a function of viral load measured in a single cross-
sectional survey while we need the distribution of 
the set-point viral load which is the incidence of 
prevalent cases. To do this we divide the prevalence 
data in Figure 1 by the survival and redo the 
calculation. Since this give a new survival function 
we then iterate to convergence. This gives the 
results shown in Figure 10. 
 The distribution of set-point viral loads, 
calculated in this way, is then very close to a log-
normal distribution, as suggested by Fraser et al.,40 
with a mean value of the log10(viral load/mm3) of 
5.14 and a standard deviation of 0.78.  
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Figure 10. Survival (S) in years plotted against the 
logarithm of the viral load (L). A. The fitted line is S = 
58.4−9.00L. 
 As a check on this relationship we compare the 
relationship implied by the data in Figure 10 with 
the direct data on survival, pre-ART, given by 
Arnaout et al.41 Fitting a log-linear model to these 
data41 gives a slope of −6.7 ± 2.7 so that the slopes 
are not significantly different. However, the 
survival times are much shorted in the data from 
Arnaout et al.41 The mean value of the log10(viral 
load/mm3) is 4.7 at which point the survival is 
about 7 years whereas the corresponding survival in 
Figure 10 gives a survival time of about 16 years. 
The slope of the lines is similar but the intercept 
differs by about 2 years. We note also that in the 
study by Mellors et al.42 mean value of the 
log10(viral load/mm3) was 4.1 which is still lower 
than the value in the study by Arnaout et al.41 These 
differences may well be due to differences in the 
populations studied. 
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